K. M. Lima, S. A. dos Santos, R. R. Santos, I. T. Brandao, J. M. Rodrigues Jr. and C. L. Silva, “Efficacy of DNA HSP65 Vaccination for Tuberculosis Varies with Method of DNA Introduction in Vivo,” Vaccine, Vol. 22, No. 1, 2003, pp. 49-56. doi:10.1016/S0264-410X(03)00543-7

has been cited by the following article:

• TITLE: Ub Combination Enhanced Cellular Immune Response Elicited by HSP65 DNA Vaccine against Mycobacterium tuberculosis

  AUTHORS: Qingmin Wang, Chengxiang Lei, Qiuhong Liu

  KEYWORDS: Mycobacterium tuberculosis; HSP65; Ubiquitin; Immune Response

  JOURNAL NAME: World Journal of Vaccines, Vol.3 No.3, August 20, 2013

  ABSTRACT: This study observed the immune response induced by a HSP65 DNA vaccine fused with UbGR against Mycobacterium tuberculosis. BALB/c mice were inoculated with HSP65 DNA vaccine, UbGR-fused HSP65 DNA vaccine (Ub-GR-HSP65) and blank vector respectively. HSP65 DNA vaccine elicited a Thl-polarized immune response. The Thl-type cytokine (IFN-γ) and proliferative T cell responses from spleen were improved significantly in UbGR-HSP65 group, compared with those in HSP65 DNA vaccine group. Furthermore, this fusion DNA vaccine also led to an increased ratio of IgG2ato IgGl and the cytotoxicity of T cells. IFN-γ intracellular staining of splenocytes indicated that UbGR-HSP65 fusion DNA vaccine could activate CD4+ and CD8+ T cells, with much higher CD8+ T cells. Thus, this study demonstrated that the UbGR fusion could improve HSP65-specific cellular immune responses, which is helpful to protect against TB infection.